Funding for this research was provided by:
FP7 Health (278232)
Text and Data Mining valid from 2019-11-28
Received: 24 July 2019
Accepted: 27 September 2019
First Online: 28 November 2019
Ethics approval and consent to participate
: All procedures in the study were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: All authors give their consent for publication.
: JMC has served as a speaker for Novartis, Astellas, Pfizer, Merck Sharp & Dohme, Janssen, and AstraZeneca. PR has received lecture and advisory board fees from Pfizer, MSD, Novartis, and Gilead. During the last 2 years, GD has received advisory board and honoraria/lecture fees from Merck, USA; Gilead, UK; Infectopharm, Germany; Nabriva, USA; Cipla, India; Glenmark, India; Pfizer, Taiwan; and Bayer, Germany. The other authors declare that they have no competing interests.